Form D · Venture Capital Fund

Remiges BioPharma Fund, LP

Cambridge, MA · CIK 0001609623

Offering snapshot reported Mar 9, 2017 · SEC filing

Reported sold: $80M
Investors reported: 4
Minimum accepted: $0
First sale: Jun 6, 2014

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$70,000,000 → $80,000,000
Reported investors3 → 4

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Mar 9, 2017	Amendment	$80,000,000	$10,000,000vs Jul 8, 2014	4	SEC filing
Jul 8, 2014	Amendment	$70,000,000	No comparison	3	SEC filing
Jun 4, 2014	Initial	Yet to sell	No comparison	0	SEC filing

Offering details

Securities: Pooled investment fund
Exemptions: 06b, 3C, 3C.1
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-218532

Source: Form D, filed Mar 9, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

REMIGES BIOPHARMA FUND, LP

Investment adviser: REMIGES VENTURES, INC.

Gross asset value: $80M
Beneficial owners: 6
ADV minimum commitment: $0

Reported in Form ADV on Jan 9, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator ALTER DOMUS NEW YORK, New York, United States Investor statements: Yes (provided to all investors) Related to adviser: No

Auditor GRANT THORNTON NEW YORK, New York, United States

Provider details

Annual audit: Yes
Prime brokers: No
Custodians: No
Administrator other than the adviser: Yes
External marketing: No

GRANT THORNTON
PCAOB 248

Filing source

Form ADV 2033599 · Jan 9, 2026 · Schedule D 7.B.(1), fund 805-6741656208

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

Related funds

Funds whose names form a numbered series with this one and that share its city or the name of a related person. Form D does not state how these funds are related.

Fund	Latest Form D	Reported sold	Investors
Remiges BioPharma Fund, LP (this fund)	Mar 9, 2017	$80,000,000	4
Remiges BioPharma Fund II, LP	Jun 20, 2019	Yet to sell	0

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Taro Inaba	Director
Walter Olesiak	Director, Executive
N/A Remiges Biopharma Fund Gp, Inc.	Executive

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

One Broadway, 14 Th Floor
Cambridge, MA, 02142